[ Low Graphics ]  [ Print Friendly ]
WelcomeAbout us
Consultations About prostate cancer Treatment Research Support groups Contact past patients Ask your doctor Ask us
Current research
Genes may affect out-come
Genetic polymorphisms influence the outcome
Post-operative radiotherapy
External beam radiotherapy results
Improved detection of prostate cancer
12 year follow up data show high cure rate
Long term hormones beneficial
Which Low PSA patients to biopsy?
Pre-operative PSA velocity is prognostic
Finasteride reduces incidence
Sexual potency
Pertuzumab
Home
About us
Request a consultation
About prostate cancer
Treatment options
Support groups
Contact past patients
Questions to ask your doctor
Ask us a question
Recommended Reading
Feedback
Disclaimer
EGFR/HER-2 inhibition
higher diagnostic efficiency in prostate Ca
Current Research Into Prostate Cancer
In prostate cancer there are a number of very important problems that require elucidation.  Probably one of the most important is to try and develop new tests for prostate cancer.  We know that the PSA test is a poor test, in that it has a low level of accuracy in the diagnosis of malignancy.  It would be wonderful to have a new test that was much more specific to prostate cancer.  Some prostate cancer is benign and some malignant.  It would be fabulous if a test became available which allowed us to distinguish which prostate cancer is virulent and requires urgent treatment and which varieties of prostate cancer are more indolent and may be watched. 
 
The other big problem in prostate cancer for patients is, of course, the problem of relapse.  By this is meant the increase in the cancer’s activity after a period of response to treatment.  If one could understand the biological processes that lead to this step and control them, then it might be possible for man to live longer, live in some sort of peaceful equilibrium with his cancer. 
 
In the meantime, here are recent studies on prostate cancer:

 Prostate Cancer Research - Page 1 of 2
13 Pages Found 
PCA3 gene testing more accurately predicts those men with early prostate cancer
THe PCA3 gene test - carried out on urine samples taken after digital rectal examination - can identify men who are more likely to have a positive biopsy for cancer, as compared t o the predictive...
Pertuzumab fails to live up to promise in hormone resistant prostate cancer
In a recent multi-institutional trial from USA, the authors gave the drug pertuzumab to a group of patients with hormone resistant prostate cancer and observed any clinical responses. The rationale...
Impact of gene polymorphisms on the outcome of prostate cancer
The prognosis (outcome in terms of survival) of advanced prostate cancer differs between individuals. Whilst differences in the constitution of tumours differs and may account for much the individual...
Genetic polymorphisms influence the outcome in prostate cancer
The prognosis of prostate cancer varies between individuals. It has always been assumed that this is due to intrinsic differences in the make-up the tumour cells and  the tumour grading (assessed...
Post-operative radiotherapy confirmed in T3 disease
In patients who have undergone radical prostatectomy and found to have positive margins microscopically in the resection specimen, there are now good data to support the routine use of post-operative...
Results of external beam radiotherapy in 4839 patients
Dr. M Pisansky presented data at the recent ASTRO meeting on 4839 men with T1-T2 (early) Prostate cancer treated with external beam radiotherapy. Although there are many other such series, this is of...
Pre-operative PSA velocity is prognostic
A recent study from Stanford, California found that the rate of rise of PSA before radical prostatectomy (or probably any other form of radical therapy - but this was not examined) was prognostic....
Improved detection of prostate cancer
A recent publication in the influential Journal of Clinical Oncology has helped to determine which men with borderline raised PSA levels should proceed to biopsy. Where the PSA density (Absolute PSA...
12 year follow up data show high cure rate
Twelve years after brachytherapy for localised prostate cancer, the actuarial analysis of 1449 patients implanted at the New York Prostate Cancer Institute (stages T1c-T2c) gave overall and disease...
Improved selection of low PSA patients requiring prostate biopsy
In a recently published article in the influential J. Clin. Oncol. (Vol 23, pages 4322-9), the authors have investigated which patients with low PSA levels (less than 10) should proceed to biopsy....

 

Jump to: [ 1 2 ]

 
© 2005 N Plowman - Disclaimer - Contact Us
Site development : Intuition Communication
Generated: 14/07/2006   |   Modified: 14/07/2006 by Site Administrator   [ Login ]